JPH0437803B2 - - Google Patents
Info
- Publication number
- JPH0437803B2 JPH0437803B2 JP59198084A JP19808484A JPH0437803B2 JP H0437803 B2 JPH0437803 B2 JP H0437803B2 JP 59198084 A JP59198084 A JP 59198084A JP 19808484 A JP19808484 A JP 19808484A JP H0437803 B2 JPH0437803 B2 JP H0437803B2
- Authority
- JP
- Japan
- Prior art keywords
- capsules
- present
- composition
- tocopherol
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- 150000003611 tocopherol derivatives Chemical class 0.000 claims description 7
- 150000003704 vitamin D3 derivatives Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 3
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 3
- 229960002535 alfacalcidol Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- -1 saturated fatty acid triglycerides Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 150000003398 sorbic acids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19808484A JPS6176416A (ja) | 1984-09-20 | 1984-09-20 | 活性型ビタミンｄ↓３誘導体のカプセル剤用組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19808484A JPS6176416A (ja) | 1984-09-20 | 1984-09-20 | 活性型ビタミンｄ↓３誘導体のカプセル剤用組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3361432A Division JPH0774149B2 (ja) | 1991-12-27 | 1991-12-27 | 硬ゼラチンカプセル |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6176416A JPS6176416A (ja) | 1986-04-18 |
| JPH0437803B2 true JPH0437803B2 (fr) | 1992-06-22 |
Family
ID=16385243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19808484A Granted JPS6176416A (ja) | 1984-09-20 | 1984-09-20 | 活性型ビタミンｄ↓３誘導体のカプセル剤用組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6176416A (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE58468B1 (en) * | 1984-10-25 | 1993-09-22 | Warner Lambert Co | Method for sealing capsules and capsule |
| US4797405A (en) * | 1987-10-26 | 1989-01-10 | Eli Lilly And Company | Stabilized pergolide compositions |
| AU2004264958B2 (en) | 2003-08-13 | 2010-04-15 | Biocon, Ltd | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| JP6127295B2 (ja) * | 2015-03-10 | 2017-05-17 | 杏林製薬株式会社 | イミダフェナシン含有口腔内速崩錠 |
| JP6212588B2 (ja) * | 2016-03-24 | 2017-10-11 | 杏林製薬株式会社 | イミダフェナシン含有口腔内速崩錠 |
| JP6303038B2 (ja) * | 2017-02-14 | 2018-03-28 | 杏林製薬株式会社 | イミダフェナシン含有口腔内速崩錠 |
| JP6303037B2 (ja) * | 2017-02-14 | 2018-03-28 | 杏林製薬株式会社 | イミダフェナシン含有口腔内速崩錠 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5312414A (en) * | 1976-07-21 | 1978-02-03 | Chugai Pharmaceut Co Ltd | Production of preparation containing stable 1alpha-hydroxyvitamines d |
| JPS5740414A (en) * | 1980-08-25 | 1982-03-06 | Teijin Ltd | Novel active type vitamin d3 derivative composition |
| JPS5740461A (en) * | 1980-08-25 | 1982-03-06 | Teijin Ltd | Novel activated vitamin d3 derivative composition |
| JPS5740415A (en) * | 1980-08-25 | 1982-03-06 | Teijin Ltd | Novel active type vitamin d3 derivative composition |
-
1984
- 1984-09-20 JP JP19808484A patent/JPS6176416A/ja active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5312414A (en) * | 1976-07-21 | 1978-02-03 | Chugai Pharmaceut Co Ltd | Production of preparation containing stable 1alpha-hydroxyvitamines d |
| JPS5740414A (en) * | 1980-08-25 | 1982-03-06 | Teijin Ltd | Novel active type vitamin d3 derivative composition |
| JPS5740461A (en) * | 1980-08-25 | 1982-03-06 | Teijin Ltd | Novel activated vitamin d3 derivative composition |
| JPS5740415A (en) * | 1980-08-25 | 1982-03-06 | Teijin Ltd | Novel active type vitamin d3 derivative composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6176416A (ja) | 1986-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1547588B1 (fr) | Preparation de capsule molle | |
| US4810497A (en) | Pharmaceutical compositions | |
| JP3527890B2 (ja) | フマル酸アルキル水素エステルからなる乾癬、乾癬性関節炎、神経皮膚炎および限局性回腸炎クローン病の治療剤 | |
| CA2803558C (fr) | Preparation a base de composes d'acide gras .omega.3 | |
| CA2432020C (fr) | Produits de coenzyme q possedant des qualites de dissolution elevees | |
| EP0184942B1 (fr) | Compositions pharmaceutiques contenant de l'acide 13-Cis vitaminique A comme ingrédient actif | |
| DE4218572A1 (de) | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E | |
| NZ203061A (en) | Propylene glycol diester solutions of pge-type compounds | |
| US20140142127A1 (en) | Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils | |
| CZ287558B6 (en) | Pharmaceutical preparation | |
| KR940021054A (ko) | 캡슐형 유비데카레논 경구 제제 | |
| JPH0437803B2 (fr) | ||
| DE2716601C2 (de) | Ein 1α-Hydroxy-Vitamin D und ein Öl enthaltendes Arzneimittel in einer Weichgelatinekapsel | |
| EP1485081B1 (fr) | Solution d'ibuprofene pour gelules dures a coque | |
| KR910014124A (ko) | 콜로이달 비스무트 서브시트레이트(cbs)를 함유하는 삼킬수 있는 투여 단위 | |
| NO158379C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive nitroalifatiske forbindelser. | |
| JPH04288016A (ja) | 活性型ビタミンｄ３類軟カプセル剤の製造方法 | |
| ATE13488T1 (de) | Gallium-chlorid, ein neues antikrebsmittel. | |
| EP0452697B1 (fr) | Stabilisateur pour une préparation contenant du 4-éthyl-2-hydroxyimino-5-nitro-3-hexénamide et méthode de stabilisation | |
| DE3306299C2 (fr) | ||
| EP0966455B1 (fr) | Acides carboxyliques d'oxirane s'utilisant dans le traitement du diabete | |
| HU228857B1 (en) | Stable formulation containing fumagillin | |
| US4150141A (en) | Treatment for scabies | |
| JPH0687750A (ja) | 医薬組成物 | |
| JPH0234325B2 (ja) | Shishushitsukanchiryoyososeibutsu |